
Jan 22 (Reuters) - Hoth Therapeutics Inc HOTH.O:
HOTH THERAPEUTICS DELIVERS 100% CLINICAL RESPONSE WITH ~50% REDUCTION IN DISEASE SEVERITY IN OPEN-LABEL PK COHORT OF EGFR-TREATED CANCER PATIENTS
HOTH THERAPEUTICS INC - HT-001 WELL TOLERATED WITH NO UNEXPECTED SAFETY SIGNALS
HOTH THERAPEUTICS INC - ADDITIONAL ENDPOINTS SHOW ~34% IMPROVEMENT IN ONCOLOGY TOXICITY